A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies von Davids, Matthew S, Brander, Danielle M, Alvarado Valero, Yesid, Diefenbach, Catherine Sibyl, Egan, Daniel Nathan, Dinner, Shira Naomi, Javidi-Sharifi, Nathalie, Al Malki, Monzr M, Begna, Kebede, Bhatt, Vijaya R, Abedin, Sameem, Cook, Rachel, Collins, Mary C, Roleder, Carly, Dominguez, Edward C, Rajagopalan, Prabhu, Wiley, Sandra E, Ghalie, Richard G, Danilov, Alexey V

Volltext